Advances in progesterone delivery systems: Still work in progress?

[Display omitted] Progesterone is a natural steroidal sex hormone in the human body, mainly secreted through the adrenal cortex, ovary, and placenta. In humans, progesterone is essential for endometrium transformation in the uterus at the time of ovulation and maintenance of pregnancy. When the body...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of pharmaceutics 2023-08, Vol.643, p.123250-123250, Article 123250
Hauptverfasser: Patil, Nikhil, Maheshwari, Ronak, Wairkar, Sarika
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 123250
container_issue
container_start_page 123250
container_title International journal of pharmaceutics
container_volume 643
creator Patil, Nikhil
Maheshwari, Ronak
Wairkar, Sarika
description [Display omitted] Progesterone is a natural steroidal sex hormone in the human body, mainly secreted through the adrenal cortex, ovary, and placenta. In humans, progesterone is essential for endometrium transformation in the uterus at the time of ovulation and maintenance of pregnancy. When the body cannot produce enough progesterone for specific ailments, it is administered via different routes such as oral, vaginal, transdermal, topical, parental, and intranasal routes. Although progesterone is commercially available in multiple conventional formulations, low solubility, less permeability and extensive hepatic first-pass metabolism are the major constraints to its delivery. These challenges can be overcome substantially by formulating progesterone into novel delivery systems like lipid carriers, polymeric carriers, hydrogels, several nanocarriers, depot and controlled release systems. Various research papers and patents have been published in the last two decades on progesterone delivery systems; clinical studies were conducted to establish safety and efficacy. This review is focused on the pharmacodynamic and pharmacokinetic parameters of progesterone, its delivery constraints, and various advanced delivery systems of progesterone.
doi_str_mv 10.1016/j.ijpharm.2023.123250
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2841024804</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0378517323006701</els_id><sourcerecordid>2841024804</sourcerecordid><originalsourceid>FETCH-LOGICAL-c365t-3be5ca77ca52ba48bbc62fb836a01ceaee37021dd439a687536f6cf5459683f33</originalsourceid><addsrcrecordid>eNqFkE1PwzAMhiMEYmPwE0A9culI4uZjXKYx8SVN4gCcozR1IaNdR9IN7d_TaRtXTpasx37th5BLRoeMMnkzH_r58tOGesgphyHjwAU9In2mFaSQKXlM-hSUTgVT0CNnMc4ppZIzOCU9UJlmdCT75G5SrO3CYUz8IlmG5gNji6FZYFJg5dcYNkncdK063iavra-q5KcJXwc4YIzjc3JS2irixb4OyPvD_dv0KZ29PD5PJ7PUgRRtCjkKZ5VyVvDcZjrPneRlrkFayhxaRFCUs6LIYGSlVgJkKV0pMjGSGkqAAbne7e2Sv1fdnab20WFV2QU2q2i4zhjlmaZZh4od6kITY8DSLIOvbdgYRs1Wn5mbvT6z1Wd2-rq5q33EKq-x-Js6-OqA8Q7A7tG1x2Ci89j5K3xA15qi8f9E_AJutoOi</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2841024804</pqid></control><display><type>article</type><title>Advances in progesterone delivery systems: Still work in progress?</title><source>Elsevier ScienceDirect Journals Complete - AutoHoldings</source><creator>Patil, Nikhil ; Maheshwari, Ronak ; Wairkar, Sarika</creator><creatorcontrib>Patil, Nikhil ; Maheshwari, Ronak ; Wairkar, Sarika</creatorcontrib><description>[Display omitted] Progesterone is a natural steroidal sex hormone in the human body, mainly secreted through the adrenal cortex, ovary, and placenta. In humans, progesterone is essential for endometrium transformation in the uterus at the time of ovulation and maintenance of pregnancy. When the body cannot produce enough progesterone for specific ailments, it is administered via different routes such as oral, vaginal, transdermal, topical, parental, and intranasal routes. Although progesterone is commercially available in multiple conventional formulations, low solubility, less permeability and extensive hepatic first-pass metabolism are the major constraints to its delivery. These challenges can be overcome substantially by formulating progesterone into novel delivery systems like lipid carriers, polymeric carriers, hydrogels, several nanocarriers, depot and controlled release systems. Various research papers and patents have been published in the last two decades on progesterone delivery systems; clinical studies were conducted to establish safety and efficacy. This review is focused on the pharmacodynamic and pharmacokinetic parameters of progesterone, its delivery constraints, and various advanced delivery systems of progesterone.</description><identifier>ISSN: 0378-5173</identifier><identifier>EISSN: 1873-3476</identifier><identifier>DOI: 10.1016/j.ijpharm.2023.123250</identifier><identifier>PMID: 37481096</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Contraceptive ; Delivery constraints ; Novel delivery systems ; Pharmacokinetic parameters ; Progesterone</subject><ispartof>International journal of pharmaceutics, 2023-08, Vol.643, p.123250-123250, Article 123250</ispartof><rights>2023 Elsevier B.V.</rights><rights>Copyright © 2023 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c365t-3be5ca77ca52ba48bbc62fb836a01ceaee37021dd439a687536f6cf5459683f33</citedby><cites>FETCH-LOGICAL-c365t-3be5ca77ca52ba48bbc62fb836a01ceaee37021dd439a687536f6cf5459683f33</cites><orcidid>0000-0002-0124-1741</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ijpharm.2023.123250$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,778,782,3539,27907,27908,45978</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37481096$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Patil, Nikhil</creatorcontrib><creatorcontrib>Maheshwari, Ronak</creatorcontrib><creatorcontrib>Wairkar, Sarika</creatorcontrib><title>Advances in progesterone delivery systems: Still work in progress?</title><title>International journal of pharmaceutics</title><addtitle>Int J Pharm</addtitle><description>[Display omitted] Progesterone is a natural steroidal sex hormone in the human body, mainly secreted through the adrenal cortex, ovary, and placenta. In humans, progesterone is essential for endometrium transformation in the uterus at the time of ovulation and maintenance of pregnancy. When the body cannot produce enough progesterone for specific ailments, it is administered via different routes such as oral, vaginal, transdermal, topical, parental, and intranasal routes. Although progesterone is commercially available in multiple conventional formulations, low solubility, less permeability and extensive hepatic first-pass metabolism are the major constraints to its delivery. These challenges can be overcome substantially by formulating progesterone into novel delivery systems like lipid carriers, polymeric carriers, hydrogels, several nanocarriers, depot and controlled release systems. Various research papers and patents have been published in the last two decades on progesterone delivery systems; clinical studies were conducted to establish safety and efficacy. This review is focused on the pharmacodynamic and pharmacokinetic parameters of progesterone, its delivery constraints, and various advanced delivery systems of progesterone.</description><subject>Contraceptive</subject><subject>Delivery constraints</subject><subject>Novel delivery systems</subject><subject>Pharmacokinetic parameters</subject><subject>Progesterone</subject><issn>0378-5173</issn><issn>1873-3476</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNqFkE1PwzAMhiMEYmPwE0A9culI4uZjXKYx8SVN4gCcozR1IaNdR9IN7d_TaRtXTpasx37th5BLRoeMMnkzH_r58tOGesgphyHjwAU9In2mFaSQKXlM-hSUTgVT0CNnMc4ppZIzOCU9UJlmdCT75G5SrO3CYUz8IlmG5gNji6FZYFJg5dcYNkncdK063iavra-q5KcJXwc4YIzjc3JS2irixb4OyPvD_dv0KZ29PD5PJ7PUgRRtCjkKZ5VyVvDcZjrPneRlrkFayhxaRFCUs6LIYGSlVgJkKV0pMjGSGkqAAbne7e2Sv1fdnab20WFV2QU2q2i4zhjlmaZZh4od6kITY8DSLIOvbdgYRs1Wn5mbvT6z1Wd2-rq5q33EKq-x-Js6-OqA8Q7A7tG1x2Ci89j5K3xA15qi8f9E_AJutoOi</recordid><startdate>20230825</startdate><enddate>20230825</enddate><creator>Patil, Nikhil</creator><creator>Maheshwari, Ronak</creator><creator>Wairkar, Sarika</creator><general>Elsevier B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-0124-1741</orcidid></search><sort><creationdate>20230825</creationdate><title>Advances in progesterone delivery systems: Still work in progress?</title><author>Patil, Nikhil ; Maheshwari, Ronak ; Wairkar, Sarika</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c365t-3be5ca77ca52ba48bbc62fb836a01ceaee37021dd439a687536f6cf5459683f33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Contraceptive</topic><topic>Delivery constraints</topic><topic>Novel delivery systems</topic><topic>Pharmacokinetic parameters</topic><topic>Progesterone</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Patil, Nikhil</creatorcontrib><creatorcontrib>Maheshwari, Ronak</creatorcontrib><creatorcontrib>Wairkar, Sarika</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of pharmaceutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Patil, Nikhil</au><au>Maheshwari, Ronak</au><au>Wairkar, Sarika</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Advances in progesterone delivery systems: Still work in progress?</atitle><jtitle>International journal of pharmaceutics</jtitle><addtitle>Int J Pharm</addtitle><date>2023-08-25</date><risdate>2023</risdate><volume>643</volume><spage>123250</spage><epage>123250</epage><pages>123250-123250</pages><artnum>123250</artnum><issn>0378-5173</issn><eissn>1873-3476</eissn><abstract>[Display omitted] Progesterone is a natural steroidal sex hormone in the human body, mainly secreted through the adrenal cortex, ovary, and placenta. In humans, progesterone is essential for endometrium transformation in the uterus at the time of ovulation and maintenance of pregnancy. When the body cannot produce enough progesterone for specific ailments, it is administered via different routes such as oral, vaginal, transdermal, topical, parental, and intranasal routes. Although progesterone is commercially available in multiple conventional formulations, low solubility, less permeability and extensive hepatic first-pass metabolism are the major constraints to its delivery. These challenges can be overcome substantially by formulating progesterone into novel delivery systems like lipid carriers, polymeric carriers, hydrogels, several nanocarriers, depot and controlled release systems. Various research papers and patents have been published in the last two decades on progesterone delivery systems; clinical studies were conducted to establish safety and efficacy. This review is focused on the pharmacodynamic and pharmacokinetic parameters of progesterone, its delivery constraints, and various advanced delivery systems of progesterone.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>37481096</pmid><doi>10.1016/j.ijpharm.2023.123250</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0002-0124-1741</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0378-5173
ispartof International journal of pharmaceutics, 2023-08, Vol.643, p.123250-123250, Article 123250
issn 0378-5173
1873-3476
language eng
recordid cdi_proquest_miscellaneous_2841024804
source Elsevier ScienceDirect Journals Complete - AutoHoldings
subjects Contraceptive
Delivery constraints
Novel delivery systems
Pharmacokinetic parameters
Progesterone
title Advances in progesterone delivery systems: Still work in progress?
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T15%3A31%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Advances%20in%20progesterone%20delivery%20systems:%20Still%20work%20in%20progress?&rft.jtitle=International%20journal%20of%20pharmaceutics&rft.au=Patil,%20Nikhil&rft.date=2023-08-25&rft.volume=643&rft.spage=123250&rft.epage=123250&rft.pages=123250-123250&rft.artnum=123250&rft.issn=0378-5173&rft.eissn=1873-3476&rft_id=info:doi/10.1016/j.ijpharm.2023.123250&rft_dat=%3Cproquest_cross%3E2841024804%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2841024804&rft_id=info:pmid/37481096&rft_els_id=S0378517323006701&rfr_iscdi=true